Tech that helps people outshone overhyped AI at CES 2026

CES 2026 was dominated by AI branding but exposed substantial gaps between hype and usable consumer products, with pervasive privacy concerns around AI-enabled toothbrushes, toilets and household robots. NVIDIA used the show to unveil Vera Rubin silicon for AI training/inference and the Alpamayo autonomous-vehicle platform—moves that could support semiconductor and automotive software vendors if execution and regulatory/safety hurdles are cleared—while several non-AI assistive technologies (Lili Screen, SeeHaptic, Glidance, MakeSense) demonstrated clearer near-term user value.

Analysis

Market structure: CES underlined a bifurcation — durable winners are AI infrastructure and select healthcare/device innovators, losers are commoditized consumer gadget vendors. Expect sustained GPU/accelerator pricing power for 12–24 months as datacenter training demand outstrips incremental supply, but downward pressure on retail hardware ASPs as "AI-enabled" labeling fails to justify premiums.

Risk assessment: Key tail risks include a major privacy/regulatory action (5–15% probability next 12 months) that could compress multiples 10–25% for data-dependent firms, and an AV or robot safety incident that delays commercialization by 12–36 months. Short-term (days–weeks) headlines will drive volatility; medium-term (3–12 months) depend on chip cadence (new silicon launches) and supply-chain tightness at TSMC/ASML.

Trade implications: Favor concentrated semiconductor exposure (NVDA, SOXX) with explicit hedges; overweight medical-device exposure (IHI) to capture non-hyped, high-utility wins from CES over 12–36 months. Trim/avoid small-cap consumer IoT hardware and reduce exposure to cyclical retail (BBY) where margin compression and returns risk are highest; use options (protective puts, covered calls) to manage asymmetric risk.

Contrarian angles: Consensus misses the reallocation risk — capital will rotate from flashy consumer AI to enterprise/infra and accessibility healthcare over 6–18 months, creating relative alpha for semicap equipment and med-devs. Historical parallel: 2014 wearables hype followed by 2–3 year value shift to platform and component suppliers; an unintended consequence is that regulatory backlash could further concentrate profits in a smaller set of high-moat infra names.

Key Decisions for Investors

• Establish a 2–3% long position in NVDA (ticker NVDA) sized to portfolio risk budget with a 12–24 month horizon; immediately buy 3-month puts ~7.5% OTM sized to cover 50% of the position as downside insurance; enter on any pullback >5% in next 30 days or scale in over 2 tranches.
• Allocate 3–4% to SOXX (semiconductor ETF) for 12 months to capture capex cycle; sell 1–2% covered calls 6–8% OTM with 3-month expiries to generate yield and trim exposure if SOXX rallies >25% from entry.
• Initiate a 1.5–2% long in IHI (medical devices ETF) to play assistive/healthcare tech adoption over 12–36 months; increase to 3–4% if M&A or FDA-clearance headlines occur, or if IHI underperforms semis by >10% in 6 months.
• Reduce/trim exposure to consumer electronics/retail (example: reduce BBY position by 50% if currently overweight) and reallocate proceeds to NVDA/SOXX/IHI; if unable to trim stock-level positions, initiate a 0.5–1% notional short via options or inverse retail ETF to express caution over commoditization risk.